58 completed, 9 active not recruiting, 8 recruiting, 8 unknown. 29 Phase 2, 26 Phase 3, 16 Phase 4, 9 Phase 1, 8 Not applicable.
Follow Wet Macular Degeneration: new trials by email Literature Review of Wet Macular Degeneration trials Research Report on Wet Macular Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LEAP Strategy for Neovascular Age-Related Macular Degeneration Laser photocoagulation, Anti-VEGF agents - Neovascular Age-related Macular Degeneration(nAMD), Wet Macular Degeneration | Not applicable | Not yet recruiting | Chinese PLA General Hospital | 240 | 2026-08-01 | 2026-08-19 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-04-15 | 2026-08-06 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-03-27 | 2026-10-02 |
| Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 3 | Recruiting | 4D Molecular Therapeutics | 480 | 2025-07-22 | 2026-10-19 |
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) - Macular Neovascularization Secondary to Age-Related Macular Degeneration | Phase 3 | Active not recruiting | 4D Molecular Therapeutics | 480 | 2025-03-03 | 2026-06-01 |
| A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) bevacizumab, ranibizumab - Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration | Phase 3 | Completed | Outlook Therapeutics, Inc. | 400 | 2024-01-24 | 2026-07-23 |
| NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration NG101 AAV gene therapy - Age-Related Macular Degeneration | Phase 1 / Phase 2 | Active not recruiting | Elisigen, Inc. | 20 | 2023-09-08 | 2026-09-10 |
| Artificial Intelligence Diagnostic Aid Macusense Assessment Software - Wet Macular Degeneration, Diabetic Macular Edema | Unknown | Guy's and St Thomas' NHS Foundation Trust | 422 | 2023-06-01 | 2023-05-18 | |
| A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD) SYL1801 - Wet Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Sylentis, S.A. | 99 | 2022-11-22 | 2026-04-13 |
| Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] ADVM-022 - Neovascular Age-related Macular Degeneration | Phase 2 | Active not recruiting | Adverum Biotechnologies, Inc. | 69 | 2022-08-23 | 2025-08-22 |
| M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD Macular Degeneration, Wet, Metamorphopsia | Completed | Ospedale Santa Croce-Carle Cuneo | 57 | 2022-05-09 | 2023-11-02 | |
| Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) Injection Brolucizumab - Neovascular Age-related Macular Degeneration (nAMD) | Phase 4 | Completed | Novartis Pharmaceuticals | 105 | 2022-03-09 | 2025-03-20 |
| A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration Iptacopan (LNP023), Placebo - Age-Related Macular Degeneration | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 168 | 2022-02-17 | 2026-09-22 |
| Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse Ophthalmic Drugs - Wet Macular Degeneration | Completed | Sorlandet Hospital HF | 31 | 2022-02-08 | 2024-06-05 | |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
| 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration 4D-150 IVT, Aflibercept IVT - Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | 4D Molecular Therapeutics | 215 | 2021-12-09 | 2026-08-21 |
| A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders bevacizumab - Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 3 | Active not recruiting | Outlook Therapeutics, Inc. | 120 | 2021-11-15 | 2026-04-22 |
| Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. Brolucizumab - Neovascular Age-related Macular Degeneration | Phase 4 | Completed | Novartis Pharmaceuticals | 122 | 2021-10-15 | 2025-05-16 |
| Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration Wet Macular Degeneration | Terminated | Johns Hopkins University | 20 | 2021-09-01 | 2022-09-26 | |
| Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration Brolucizumab - Age-related Macular Degeneration | Phase 4 | Completed | Novartis Pharmaceuticals | 52 | 2021-07-13 | 2025-09-26 |
Showing 20 of 93. Sign in to see all of them.
Macular Degeneration (55) · Eye Diseases (18) · Vision Disorders (17) · Choroidal Neovascularization (16) · Geographic Atrophy (15) · Retinal Diseases (15) · Retinal Degeneration (13) · Retinal Vein Occlusion (8) · Blindness (5) · Macular Edema (3) · Neovascularization, Pathologic (3) · Retinal Detachment (3) · Cone Dystrophy (2) · Cone-Rod Dystrophies (2)
Retinal Degeneration (80) · Retinal Diseases (78) · Eye Diseases (75) · Macular Degeneration (38) · Pathological Conditions, Signs and Symptoms (34) · Nervous System Diseases (22) · Pathologic Processes (22) · Metaplasia (21) · Neurologic Manifestations (20) · Sensation Disorders (20) · Signs and Symptoms (20) · Neovascularization, Pathologic (18) · Choroid Diseases (17) · Uveal Diseases (17) · Eye Diseases, Hereditary (15)
aflibercept (27) · Ranibizumab (25) · Bevacizumab (8) · brolucizumab (7) · Injections (2) · Tissue Plasminogen Activator (2) · Triamcinolone Acetonide (2) · dorzolamide-timolol combination (2) · faricimab (2) · Calcium Dobesilate (1) · Dexamethasone (1) · Dietary Supplements (1) · Doxycycline (1) · Immunoglobulins, Intravenous (1) · Jupiter (1)
Novartis Pharmaceuticals (14) · Bayer (8) · Outlook Therapeutics, Inc. (5) · AbbVie (4) · 4D Molecular Therapeutics (3) · Adverum Biotechnologies, Inc. (3) · Boehringer Ingelheim (2) · Centre Hospitalier Intercommunal Creteil (2) · EyeBiotech Ltd. (2) · Hoffmann-La Roche (2) · Johns Hopkins University (2) · King's College Hospital NHS Trust (2) · MD Stem Cells (2) · Wills Eye (2) · Aier School of Ophthalmology, Central South University (1)
United States (49) · Germany (16) · Spain (14) · United Kingdom (14) · France (13) · Italy (12) · Canada (9) · Australia (8) · Puerto Rico (8) · Czechia (7) · Hungary (7) · Poland (7) · Austria (6) · China (6) · Israel (6)
Anne Fung, MD (2) · Jason Hsu, MD (2) · Jeffrey Weiss, MD (2) · Jennifer M Kissner, PhD (2) · Steven Levy, MD (2) · Adam Turpcu, PhD (1) · Andrea Russo, MD (1) · Brandon G Busbee, MD (1)
PMID 26199618, PMID 26604914, PMID 27857759, PMID 27904503, PMID 35085502, PMID 36246941, PMID 37294433, PMID 38382813, PMID 41712218, PMID 11297486, PMID 12967792, PMID 17188044, PMID 17675159, PMID 1850220, PMID 1922252, PMID 19365036, PMID 19592101, PMID 20110127, PMID 22183743, PMID 22264944, PMID 22559899, PMID 22801846, PMID 23245386, PMID 24836866, PMID 26431823, PMID 26445522, PMID 26914218, PMID 27865764, PMID 28570723, PMID 29270420, PMID 29864044, PMID 30050918, PMID 30681643, PMID 30986442, PMID 31119146, PMID 31179386, PMID 31383649, PMID 31620478, PMID 32016788, PMID 32039263, PMID 32107066, PMID 32231088, PMID 32239190, PMID 32450838, PMID 32518833, PMID 32568958, PMID 33546345, PMID 33596867, PMID 34283294, PMID 35101110
2018 (3), 2019 (3), 2014 (1), 2017 (1)